Medicare billing address
CMS Medicare provider billing file
833 Chestnut St Ste 740Philadelphia, PA 19107
CMS public data · NPI 1891157129
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Collin G Fuller, M.D.
Specialty
Credential
M.D.
NPI
1891157129
Primary source state
PA
Data retrieval date
July 26, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Collin G Fuller, M.D. from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
833 Chestnut St Ste 740CMS Doctors & Clinicians file
258 Ben Franklin Hwy ECMS Doctors & Clinicians file
10 Fila WayCMS Doctors & Clinicians file
6300 Limestone RdIn the 2024 CMS provider billing file, this NPI had 6,142 Medicare beneficiaries and 14,179 total services. The average beneficiary age was 75, and the average HCC risk score was 1.
Total Medicare allowed amount
$1,023,188.67
Total Medicare payment amount
$768,232.56
Medicare beneficiaries
6,142
Total services
14,179
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
70%
CMS beneficiary-panel share
Ischemic heart disease
25%
CMS beneficiary-panel share
Diabetes
24%
CMS beneficiary-panel share
Chronic kidney disease
20%
CMS beneficiary-panel share
Anxiety
20%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Pathology examination of tissue using a microscope, intermediate complexity | 12,249 | $69.76 |
| Special stained specimen slides to examine tissue, initial procedure | 417 | $102.90 |
| Special stained specimen slides to identify organisms including interpretation and report | 361 | $108.54 |
| Pathology examination of tissue using a microscope, moderately low complexity | 224 | $41.87 |
| Special stained specimen slides to examine tissue, each additional procedure | 181 | $87.71 |
| Destruction of precancer skin growth, 2-14 growths | 168 | $6.83 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 135 | $92.24 |
| Biopsy of related skin growth, first growth | 85 | $98.15 |
| Biopsy of related skin growth, each additional growth | 83 | $51.70 |
| Destruction of precancer skin growth, 1 growth | 56 | $52.38 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1891157129. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Ketoconazole | Ketoconazole | 428 | 441.3 | $6,404.41 |
| 2 | Clobetasol Propionate | Clobetasol Propionate | 258 | 265 | $24,051.46 |
| 3 | Triamcinolone Acetonide | Triamcinolone Acetonide | 216 | 226.8 | $3,018.68 |
| 4 | Hydrocortisone | Hydrocortisone | 113 | 113 | $1,210.85 |
| 5 | Fluocinonide | Fluocinonide | 85 | 85 | $3,618.46 |
| 6 | Mometasone Furoate | Mometasone Furoate | 67 | 70.7 | $2,043.14 |
| 7 | Metronidazole | Metronidazole | 51 | 51 | $3,153.02 |
| 8 | Clindamycin Phosphate | Clindamycin Phosphate | 45 | 46 | $2,166.96 |
| 9 | Mupirocin | Mupirocin | 39 | 39.5 | $371.66 |
| 10 | Doxycycline Hyclate | Doxycycline Hyclate | 30 | 31 | $205.90 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
2016
Group/practice field
Pennsylvania Dermatology Partners Inc
Telehealth reported
Not reported
Secondary specialty fields reported by CMS: Pathology.
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.